Capecitabine is an effective treatment in gemcitabine-refractory advanced pancreatic cancer

被引：0
|
作者：
Arrazubi, V [1 ]
Illarramendi, J. [1 ]
Lainez, N. [1 ]
Salgado, E. [1 ]
Martinez, M. [1 ]
Amillano, K. [1 ]
Vera, R. [1 ]
机构：
[1] Hosp Navarra, Pamplona, Spain
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：75 / 75
页数：1
相关论文
共 50 条
  • [41] A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer
    Chigusa Morizane
    Takuji Okusaka
    Junji Furuse
    Hiroshi Ishii
    Hideki Ueno
    Masafumi Ikeda
    Kohei Nakachi
    Mina Najima
    Takashi Ogura
    Eiichiro Suzuki
    Cancer Chemotherapy and Pharmacology, 2009, 63 : 313 - 319
  • [42] Prognostic factors for gemcitabine-refractory patients with advanced pancreatic cancer: a retrospective analysis of a multicentre study (Anatolian Society of Medical Oncology)
    Inal, Ali
    Kos, F. Tuba
    Algin, Efnan
    Yildiz, Ramazan
    Berk, Veli
    Unek, Ilkay T.
    Colak, Dilsen
    Dane, Faysal
    Geredeli, Caglayan
    Isikdogan, Abdurrahman
    WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2015, 19 (02): : 125 - 129
  • [43] Alternate Week Gemcitabine and Capecitabine An Effective Treatment for Patients With Pancreatic Adenocarcinoma
    Johns, Claire
    Diaz, Celso L.
    Hwang, Jimmy
    Kerridge, William D.
    Ko, Andrew H.
    Tempero, Margaret A.
    PANCREAS, 2019, 48 (07) : 927 - 930
  • [44] S-1 monotherapy or in combination with lencovorin as second-line treatment in gemcitabine-refractory advanced pancreatic cancer: A phase II study.
    Ge, Feijiao
    Xu, Nong
    Bai, Yuxian
    Ba, Yi
    Zhang, Yanqiao
    Li, Fei
    Xu, Huayan
    Jia, Ru
    Wang, Yan
    Lin, Li
    Xu, Jian-Ming
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [45] Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer
    Boeck, Stefan
    Wilkowski, Ralf
    Bruns, Christiane J.
    Issels, Rolf D.
    Schulz, Christoph
    Moosmann, Nicolas
    Laessig, Dorit
    Haas, Michael
    Golf, Alexander
    Heinemann, Volker
    ONCOLOGY, 2007, 73 (3-4) : 221 - 227
  • [46] JASPAC 02: A phase II study of gemcitabine and oxaliplatin (GEMOX) for gemcitabine-refractory advanced biliary tract cancer
    Ohno, I.
    Fukutomi, A.
    Furuse, J.
    Okusaka, T.
    Asayama, M.
    Nakamori, S.
    Ishii, H.
    Okuno, T.
    Yamanaka, T.
    Boku, N.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S631 - S632
  • [47] A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer.
    Morizane, C.
    Okusaka, T.
    Furuse, J.
    Ishii, H.
    Ueno, H.
    Ikeda, M.
    Najima, M.
    Hirokawa, S.
    Nakachi, K.
    Ogura, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 206S - 206S
  • [48] Paclitaxel as second-line chemotherapy in patients with gemcitabine-refractory pancreatic cancer: a retrospective study
    Maeda, Shimpei
    Motoi, Fuyuhiko
    Onogawa, Tohru
    Morikawa, Takanori
    Shigeru, Ottomo
    Sakata, Naoaki
    Takadate, Tatsuyuki
    Naitoh, Takeshi
    Rikiyama, Toshiki
    Katayose, Yu
    Egawa, Shinichi
    Unno, Michiaki
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2011, 16 (05) : 539 - 545
  • [49] Phase II study of 5-fluorouracil and paclitaxel in patients with gemcitabine-refractory pancreatic cancer
    Kim, Yoon Jae
    Bang, Seungmin
    Park, Jeong Youp
    Park, Seung Woo
    Chung, Jae Bock
    Song, Si Young
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 63 (03) : 529 - 533
  • [50] Phase II study of 5-fluorouracil and paclitaxel in patients with gemcitabine-refractory pancreatic cancer
    Yoon Jae Kim
    Seungmin Bang
    Jeong Youp Park
    Seung Woo Park
    Jae Bock Chung
    Si Young Song
    Cancer Chemotherapy and Pharmacology, 2009, 63 : 529 - 533
12345